2,6,9-Trisubstituted Purines for Selective CDK2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological agents lack specificity and exhibit off-target toxicities in inhibiting cyclin-dependent kinase 2 (CDK2) activity, which is crucial for treating CDK2-mediated conditions such as cancer, due to poor understanding of CDK2 degradation mechanisms and sequence similarity among CDKs.
Innovation Solution
Development of 2,6,9-trisubstituted purine compounds and their pharmaceutically acceptable salts, designed to selectively inhibit CDK2 activity, potentially in combination with CDK4/6 inhibitors, for treating CDK2-mediated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological agents are used to inhibit CDK2 activity, then CDK2-mediated conditions can be treated, but the agents lack specificity and exhibit off-target toxicities
Solution Approach 1:
The patent applies local quality by designing the purine compound with specific substituent patterns at positions 2, 6, and 9 of the purine ring. These localized structural modifications create a molecule that selectively binds to CDK2's unique binding site features, allowing specific inhibition of CDK2 while sparing other CDK family members that have different binding site characteristics
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical properties of substituents at different positions on the purine ring. By adjusting parameters such as hydrophobicity, hydrogen bonding capacity, and steric bulk of the R1-R6 groups, the compound achieves optimal selectivity for CDK2 over other CDKs, resolving the contradiction between efficacy and specificity
2Reliability
If CDK2 inhibitors are developed to treat cancer, then tumor growth can be inhibited, but the inhibitors generally lack the requisite specificity
Solution Approach 1:
The patent applies segmentation by dividing the purine molecule into distinct functional regions: the core purine structure provides baseline CDK binding, while separate substituent groups at positions 2, 6, and 9 provide specificity-determining interactions. This modular design allows each region to be optimized independently for its specific function, achieving high specificity without excessive overall molecular complexity
Solution Approach 2:
The patent employs universality by designing a purine scaffold that serves multiple functions: it maintains affinity for the CDK ATP-binding site while simultaneously providing specificity through targeted interactions with CDK2-unique residues. The same molecular framework achieves both binding and selectivity, avoiding the need for overly complex multi-component structures
3Reliability
If CDK2 inhibitors are designed with high specificity, then off-target toxicities are reduced, but the mechanism of CDK2 degradation remains poorly understood
Solution Approach 1:
The patent applies the intermediary principle by using the purine compound as a molecular probe that mediates between the known CDK2 binding site and the unknown degradation mechanism. The high-specificity compound selectively binds to CDK2 in cellular contexts, allowing researchers to trace and understand CDK2's role in degradation pathways without the confounding effects of off-target binding that would obscure mechanistic insights
Data Source
AI summary
Compounds having the structure of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.